[Highly malignant non-Hodgkin's lymphomas]

Area of Science:

• Hematology
• Oncology
• Pathology

Context:

• High-grade malignant non-Hodgkin's lymphomas (NHL) are rare but increasing hematologic malignancies.
• Accurate histological classification and thorough staging are critical for effective NHL management.
• Current treatment paradigms primarily involve chemotherapy, with radiation reserved for specific cases.

Purpose:

• To review current management strategies for high-grade malignant non-Hodgkin's lymphomas.
• To discuss the efficacy of conventional and novel treatment regimens.
• To highlight challenges and advancements in treating specific patient populations, including HIV-associated and elderly patients.

Summary:

• Conventional CHOP chemotherapy remains a benchmark, with no modern intensive regimens demonstrating superiority.
• Bone marrow transplantation (autologous or allogeneic) is the preferred option for treatment failures.
• Research is ongoing to determine the benefit of bone marrow transplantation in first remission for NHL.
• Intensive chemotherapy with growth factors shows promise for HIV-associated lymphomas.
• Treatment for elderly patients remains complex, with ongoing efforts to optimize outcomes with tailored regimens.

Impact:

• Establishes the current standard of care for high-grade NHL.
• Identifies bone marrow transplantation as a key therapeutic option for refractory disease.
• Guides future research directions, particularly concerning early transplantation and elderly patient management.
• Addresses the growing clinical challenge of HIV-associated lymphomas.